Every list of semax benefits mixes two very different things. One is a Russian stroke approval built on clinic use. The other is a stack of rat studies. The human evidence outside stroke is a single 2020 imaging trial in 52 healthy adults.
The short answer. Semax has one published human study outside Russian stroke care: a 2020 fMRI trial in 52 healthy adults.
- That trial measured brain connectivity, not memory or attention, so it cannot support the focus claim.
- The mood and antistress evidence is four rat papers, including a 2024 chronic unpredictable stress model.
- The stroke work is the deepest file: rat RNA-seq showing 1,171 disrupted genes shifting back at 24 hours.
Semax is a seven-amino-acid piece of ACTH. Russia approved it as nasal drops for stroke. Most benefit claims trace back to rat studies. One human trial scanned 52 healthy adults in 2020. Zero Western randomized trials sit in PubMed. Focus and memory claims have no controlled human data.
What is Semax actually approved for?
Russia approved Semax as a nasal solution. The registered uses are acute ischemic stroke and post-stroke cognitive problems. It has been in Russian clinics for about 30 years.
That is the entire regulatory story. No Western agency has reviewed it. The FDA has never approved it for anything. A research vial sold online is not the registered nasal spray, and the approval of the spray says nothing about the vial.
Approval in one country is not trial evidence in another. Russian registration files are not indexed in PubMed. What you can read is the lab work, and the lab work is mostly rats.
The Semax complete guide covers the origin at Moscow's Institute of Molecular Genetics. The mechanism page covers how a fragment of a stress hormone ended up as a nasal drop.
Does Semax improve focus and memory?
This is the most common claim and it has the thinnest human backing of any of them.
The one human study people point to is Panikratova and colleagues, published in Doklady Biological Sciences in 2020. It used resting-state fMRI in 52 healthy adults and looked at Selank and Semax. What it reported was a change in functional connectivity, centered on the right amygdala.
- It measured brain connectivity. Not attention span, not working memory, not reaction time.
- A connectivity shift is a signal that something happened. It is not a direction. Nothing in it says the change is good.
- The amygdala is an emotion structure. If anything, that points at mood, not at focus.
- No follow-up trial exists. Zero Western randomized trials of Semax for cognition sit in PubMed.
So the nootropic claim rests on a scan, plus rodent behavior work, plus a lot of forum reports. People who sell it describe an onset in minutes. No controlled human study has measured that.
Does Semax help anxiety or depression?
The mood claim has more studies behind it than the focus claim. All of them are animal studies.
Inozemtseva and colleagues, in the European Journal of Pharmacology in 2024, ran a chronic unpredictable stress model in male rats. They tested Semax against Melanotan II and reported antidepressant-like and antistress effects. That is a rat behavior result, in a model built to mimic depression, not a diagnosis of depression.
Two other papers fill in the biology:
- Vyunova and colleagues, 2023, in Chemical Biology & Drug Design, examined synthetic corticotropins and the GABA-receptor system. They separated direct effects from delayed ones. GABA is the brain's main calming signal.
- Glazova and colleagues, 2020, in Neuropeptides, gave Semax to white rats that had been exposed to the SSRI fluvoxamine early in life. They reported that it blunted the later behavioral and neurochemical changes.
- Svishcheva and colleagues, 2021, in the Bulletin of Experimental Biology and Medicine, looked at rat gut under restraint stress. The measure was the shape and function of the large intestine, not mood.
Read together, that is a consistent antistress story in rodents. It is also four rat papers. No human anxiety or depression trial of Semax has been published in English.
Semax
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
What does the stroke evidence actually show?
This is the strongest part of the file, and it is still animal work.
Moscow's Kurchatov Institute has run a long series of rat stroke experiments using RNA sequencing. The headline number from that series is 1,171 stroke-disrupted genes whose expression moves back toward normal, a shift they track at 24 hours. The rat work in this series used doses around 60 nmol/kg/day.
ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke.
Title of Filippenkov et al., Biomedicines, 2024The supporting papers each take one layer. Dergunova and colleagues, in Molecular Biology in 2021, reported suppression of mRNA transcripts for proinflammatory mediators after reversible brain ischemia. Sudarkina and colleagues, in the International Journal of Molecular Sciences in 2021, followed the same model at the protein level. Filippenkov and colleagues, in Genes in 2023, tracked immune gene expression in the early post-stroke period.
Every one of those is a rat with an induced stroke, dosed under lab conditions. None of them is a patient outcome. No Western Phase III stroke trial of Semax exists.
Russian clinical reports do exist. Gusev and colleagues described 12 mg a day for moderate stroke and 18 mg a day for severe stroke, over short inpatient courses. Those are hospital figures from acute stroke care, reported here only as what was administered. The stroke research page goes through the gene work, and the dosage page sets out what each study used.
Does Semax do anything for Alzheimer's?
There is real chemistry here, and it comes from outside Russia, which matters.
Two Italian groups worked on the same idea. Sciacca and colleagues, in ACS Chemical Neuroscience in 2022, tested how Semax affects copper-driven amyloid beta aggregation in artificial membrane models. Tomasello and colleagues followed in Bioinorganic Chemistry and Applications in 2025.
Semax, a copper chelator peptide, decreases the Cu(II)-catalyzed ROS production and cytotoxicity of aβ by metal ion stripping and redox silencing.
Title of Tomasello et al., Bioinorganic Chemistry and Applications, 2025Stripping a copper ion off amyloid in a model membrane is a clean, measurable result. It is also a long way from a person with dementia. There is no animal Alzheimer's study of Semax in this reference set, and no human one anywhere. The value of these two papers is that labs with no connection to the original developers reproduced a piece of the chemistry.
The benefits nobody advertises, and the table that sorts them
Some of the newer Semax work points in directions the marketing never mentions. That is usually a sign you are looking at real research rather than a sales page.
Liu and colleagues published in the British Journal of Pharmacology in 2025. They reported that Semax acts on the mu opioid receptor gene Oprm1 and aids recovery after spinal cord injury. The model was female mice, and the paper says so in its title.
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
Title of Liu et al., British Journal of Pharmacology, 2025Elagina and colleagues, in the Bulletin of Experimental Biology and Medicine in 2020, looked at lipid metabolism in diabetic rats given peptide drugs. That is a metabolic claim almost no vendor makes, which tells you how loosely the popular benefit lists are assembled.
| Claim | Best available study | Subject | What was measured |
|---|---|---|---|
| Focus, memory | Panikratova, 2020 | 52 healthy adults | fMRI connectivity, not test scores |
| Mood, stress | Inozemtseva, 2024 | Male rats | Behavior under chronic stress |
| Stroke recovery | Filippenkov, 2024 | Rats | Brain gene expression at 24 hours |
| Anti-inflammatory | Dergunova, 2021 | Rats | Proinflammatory mRNA levels |
| Amyloid, copper | Tomasello, 2025 | Model membranes | Copper binding and ROS output |
| Nerve injury | Liu, 2025 | Female mice | Oprm1 signaling, motor recovery |
| Gut, lipids | Svishcheva 2021; Elagina 2020 | Rats | Intestinal tissue; blood lipids |
One human row. Six animal or test-tube rows. That ratio is the honest answer to the query.
What would actually move Semax out of rat data?
The gap is not subtle and it is not hard to describe.
For the cognitive claim, it would take a randomized, placebo-controlled trial in healthy adults with a real endpoint. Something like a validated attention or memory battery, pre-registered, with a control arm. Nothing like that has been published.
For the stroke claim, it would take a Phase III trial run outside Russia, with modified Rankin scores at 90 days. The rat gene work is detailed and reproducible, and it still cannot answer whether a patient walks better.
The evidence base this site tracks for Semax runs to about 13 published studies. Most are rodent. That is more than many research peptides have, and far less than a benefit list implies.
If you are buying anyway, the checkable things are the paperwork, not the claims. Read the certificate of analysis, check storage requirements, and know where the legal line sits.
Semax
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Semax has one published human study outside Russian stroke care: a 2020 fMRI trial in 52 healthy adults.
- That trial measured brain connectivity, not memory or attention, so it cannot support the focus claim.
- The mood and antistress evidence is four rat papers, including a 2024 chronic unpredictable stress model.
- The stroke work is the deepest file: rat RNA-seq showing 1,171 disrupted genes shifting back at 24 hours.
- Italian labs reproduced the copper and amyloid chemistry in model membranes, independent of the developers.
- Zero Western randomized trials exist, and no regulator outside Russia has reviewed the compound.
What we're watching
Watch for benefit lists that cite "approved in Russia for 30 years" as if it were trial evidence, then attach focus, mood, fat loss and anti-aging claims to it. The registered indications are stroke and post-stroke cognitive disorders. Watch also for the word "clinical" attached to the Kurchatov gene work: it is rat brain tissue, sequenced 24 hours after an induced stroke, and the papers say so plainly.
Frequently asked questions
Are there any human studies on Semax benefits?
Outside Russian stroke practice, one. Panikratova and colleagues published resting-state fMRI in 52 healthy adults in Doklady Biological Sciences in 2020, reporting connectivity changes centered on the right amygdala. It measured brain scans, not cognitive test scores. No Western randomized controlled trial of Semax appears in PubMed.
Is Semax FDA approved?
No. Russia approved a Semax nasal solution for acute ischemic stroke and post-stroke cognitive disorders. The FDA has not approved it for any use, and no Western regulator has reviewed it. Material sold as a research vial is not the registered Russian nasal product.
Does Semax really increase BDNF?
That is the proposed mechanism, and it comes from animal work. Rat studies report effects on BDNF and NGF, along with activity at dopamine, serotonin, melanocortin, GABA and opioid pathways. No published human study has measured BDNF after Semax. Our mechanism page walks through what each pathway claim rests on.
Does Semax help with anxiety?
Only rats have been tested. Inozemtseva and colleagues reported antidepressant-like and antistress effects in a chronic unpredictable stress model in male rats in 2024. Vyunova and colleagues described effects on the GABA-receptor system in 2023. There is no human anxiety trial.
Why do stroke patients in Russia get much larger amounts than research users discuss?
Because the Russian figures come from hospital stroke care. Gusev and colleagues reported 12 mg a day for moderate stroke and 18 mg a day for severe stroke over short inpatient courses. Those are acute-care numbers from a monitored setting, reported here only as what was administered in published work.
Has anyone outside Russia replicated Semax findings?
Partly. Italian groups published copper and amyloid chemistry in 2022 and 2025, and a Chinese group published spinal cord injury work in the British Journal of Pharmacology in 2025. Those replicate mechanisms in models, not clinical benefit in people.
References
- Panikratova, Y. R., Lebedeva, I. S., Sokolov, O. Y., et al. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
- Sudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., et al. (2021). Brain protein expression profile confirms the protective effect of the ACTHPGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
- Filippenkov, I. B., Remizova, J. A., Stavchansky, V. V., et al. (2023). Synthetic adrenocorticotropic peptides modulate the expression pattern of immune genes in rat brain following the early post-stroke period. Genes, 14(7), 1382. https://doi.org/10.3390/genes14071382
- Filippenkov, I. B., Shpetko, Y. Y., Stavchansky, V. V., et al. (2024). ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke. Biomedicines, 12(12), 2830. https://doi.org/10.3390/biomedicines12122830
- Sciacca, M. F. M., Naletova, I., Giuffrida, M. L., & Attanasio, F. (2022). Semax, a synthetic regulatory peptide, affects copper-induced abeta aggregation and amyloid formation in artificial membrane models. ACS Chemical Neuroscience, 13(4), 486–496. https://doi.org/10.1021/acschemneuro.1c00707
- Tomasello, M. F., Di Rosa, M. C., Naletova, I., et al. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalyzed ROS production and cytotoxicity of aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
- Liu, R., Chen, Y., Huang, H., et al. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
- Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Y., et al. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
- Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., et al. (2023). Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects. Chemical Biology & Drug Design, 101(6), 1393–1405. https://doi.org/10.1111/cbdd.14221
- Glazova, N. Y., Manchenko, D. M., Volodina, M. A., et al. (2020). Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides, 86, 102114. https://doi.org/10.1016/j.npep.2020.102114
- Svishcheva, M. V., Mishina, Y. S., Medvedeva, O. A., et al. (2021). Morphofunctional state of the large intestine in rats under conditions of restraint stress and administration of peptide ACTH-PGP (Semax). Bulletin of Experimental Biology and Medicine, 170(3), 384–388. https://doi.org/10.1007/s10517-021-05072-z
- Elagina, A. A., Lyashev, Y. D., Lyashev, A. Y., et al. (2020). Correction of lipid metabolism disorders in diabetes mellitus with peptide drugs. Bulletin of Experimental Biology and Medicine, 168(5), 618–620. https://doi.org/10.1007/s10517-020-04764-2
- Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., et al. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain. Molecular Biology (Moscow), 55(3), 402–411. https://doi.org/10.31857/S0026898421010043